Mold-Tek Packaging (533080) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
8 Sep, 2026Executive summary
Revenue increased by 22% year-over-year in Q1FY26 to INR 240.56 crore, with EBITDA margin rising to 19.7% and net profit up 35.5%.
Sales volume grew 15% year-over-year to 11,378 MT, with all major segments except lubricants showing strong growth.
Pharma vertical crossed break-even in its first year, contributing to profit growth and rapid adoption, with major approvals and commercial orders expected.
Food and FMCG achieved 16% growth despite a shortened summer, aided by removal of printing bottlenecks and enhanced serviceability.
The company achieved its highest-ever quarterly performance, supported by innovation, product diversification, and strategic expansion.
Financial highlights
EBITDA grew 29% year-over-year to INR 47.38 crore, with EBITDA per kg rising to INR 41.64 in Q1FY26.
PAT rose 35.5% year-over-year to INR 22.40 crore, with PAT margin up to 9.31%.
Net revenue per kg increased from INR 198 to INR 211, driven by improved product mix.
EPS for Q1FY26 stood at 6.74, up from 4.97 in Q1FY25.
Cash PAT reached INR 36.43 crore in Q1FY26, up 30% year-over-year.
Outlook and guidance
Volume growth targeted at 12%-15% for the year, with revenue growth expected at 18%-20%.
Pharma segment projected to reach INR 35-36 crore this year, with potential to double next year.
Food and FMCG segment expected to sustain or exceed 16% growth, with potential for 20% in upcoming quarters.
Management confident in sustaining growth trajectory, citing strong order flow, capacity enhancements, and product innovation.
Anticipates better margins and cost recovery as capacity utilization increases in new plants.
Latest events from Mold-Tek Packaging
- Sales and EBITDA rose, but net profit fell due to higher costs; capacity expansions underway.533080
Q2 24/25 - Q1 volumes and sales grew, but higher costs and new plant ramp-up impacted profitability.533080
Q1 24/25 - Q3 FY25 saw strong revenue and EBITDA growth, but PAT fell on higher costs; pharma and exports are rising.533080
Q3 24/25 - Revenue and EBITDA rose, but net profit declined as costs increased; pharma and FMCG led growth.533080
Q4 24/25 - H1FY26 revenue up 16.05% and PAT up 24%, led by strong pharma and FMCG growth.533080
Q2 25/26 - EBITDA and PAT up nearly 20% YoY, led by pharma and FMCG growth, with strong outlook.533080
Q3 25/26 - EBITDA and PAT grew over 20% YoY, with robust Pharma and FMCG segment growth and strong FY27 outlook.533080
Q4 25/26 - Record revenue and profit growth led by pharma, food, and FMCG, with historic EBITDA per kg.533080
Q1 26/27